Nuveen
EWTX icon

Nuveen’s Edgewise Therapeutics EWTX Stock Holding History

Nuveen’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8M Buy
414,706
+78,923
+24% +$2.72M ﹤0.01% 1373
2026
Q1 		$10.6M Buy
335,783
+166,317
+98% +$4.8M ﹤0.01% 1514
2025
Q4 		$4.21M Sell
169,466
-3,241
-2% -$65.1K ﹤0.01% 1988
2025
Q3 		$2.8M Sell
172,707
-144,466
-46% -$2.05M ﹤0.01% 2155
2025
Q2 		$4.16M Buy
317,173
+114,593
+57% +$1.65M ﹤0.01% 1967
2025
Q1 		$4.46M Sell
202,580
-226,278
-53% -$5.94M ﹤0.01% 1980
2024
Q4 		$11.5M Buy
428,858
+158,452
+59% +$5.05M ﹤0.01% 1528
2024
Q3 		$7.22M Buy
270,406
+27,308
+11% +$543K ﹤0.01% 1803
2024
Q2 		$4.38M Sell
243,098
-94,906
-28% -$1.66M ﹤0.01% 2023
2024
Q1 		$6.17M Buy
338,004
+184,712
+120% +$2.94M ﹤0.01% 1866
2023
Q4 		$1.68M Buy
153,292
+806
+0.5% +$5.66K ﹤0.01% 2496
2023
Q3 		$874K Sell
152,486
-1,016
-0.7% -$6.91K ﹤0.01% 2628
2023
Q2 		$1.19M Buy
153,502
+55,678
+57% +$470K ﹤0.01% 2588
2023
Q1 		$653K Sell
97,824
-8,878
-8% -$82.3K ﹤0.01% 2741
2022
Q4 		$954K Sell
106,702
-4,907
-4% -$46K ﹤0.01% 2699
2022
Q3 		$1.1M Sell
111,609
-2,728
-2% -$27.6K ﹤0.01% 2713
2022
Q2 		$910K Buy
114,337
+4,222
+4% +$31.9K ﹤0.01% 2827
2022
Q1 		$1.15M Buy
110,115
+16,765
+18% +$216K ﹤0.01% 2766
2021
Q4 		$1.8M Buy
93,350
+64,387
+222% +$1.16M ﹤0.01% 2616
2021
Q3 		$501K Sell
28,963
-17,877
-38% -$323K ﹤0.01% 3167
2021
Q2 		$999K Buy
+46,840
New +$1.28M ﹤0.01% 3005

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nuveen's EWTX Position: Q2 2026 in Review

Nuveen increased its Edgewise Therapeutics (EWTX) stake by 24% in Q2 2026, buying an estimated $2.72M and bringing the position to 414,706 shares worth $16.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1373.

Nuveen first reported a position in EWTX in Q2 2021 and has held it in 21 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Nuveen held 414,706 shares of Edgewise Therapeutics worth $16.8M as of Q2 2026.
  • Nuveen bought 78,923 Edgewise Therapeutics shares in Q2 2026, an estimated $2.72M.
  • Edgewise Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1373 holding.
  • Nuveen first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.